is there a slight change in wording around 'progress' various potential opportunities? or am I just imagining things. Can someone check this? i'm strapped for time right now.
The other bolded parts are really great too. Dr Glass is confident that the results are worthy of attention of the ATS following on from their previous appearance. Some confidence there that things will not stall, with the start of phase 3 process in March 2016. Hopefully all is certain by then.
The Company has since submitted an abstract to the 2016 American Thoracic Society (ATS) annual meeting, and a request to the US Food and Drug Administration (FDA) for an End of Phase 2 (EOP2) meeting, to facilitate the commencement of the phase 3 program for oral INV102. The EOP2 meeting is scheduled to be held by the end of the current quarter (March 2016). Following the successful completion of major milestones across its four drug development programs during 2015, during the quarter the Board appointed Ferghana Partners Group (New York, London, Boston) to progress various potential opportunities under review. Ferghana’s expertise is in acquisitions, divestitures, corporate partnering and financial transactions in the global healthcare sector.
IVX Price at posting:
0.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)